Vical Incorporated Updates Vaccine Development Programs for CMV and Pandemic Influenza

WASHINGTON, Jan. 26, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present an overview of its DNA vaccine and adjuvant technologies and an update on its clinical-stage vaccine development programs at the Phacilitate Vaccine Forum (Washington - January 25-27). Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, is scheduled to present on Wednesday, January 27, at 12:55 p.m.

Back to news